We are developing a phase II ready asset for idiopathic pulmonary fibrosis, a deadly lung disease with an addressable market of $2.8bn.
Only investors on Gust who have been granted access can view this content.
Interested in this startup? Sign In or Sign Up to request more information.
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.
Get Started for Free